Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and posttreatment cardiological investigations. So far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (TAD/TAD - TAD/HAM).
Kraft
J
J
Dept. of Medicine, Evangelisches Krankenhaus Essen-Werden, FRG.
Grille
W
W
Appelt
M
M
Hossfeld
D K
DK
Eichelbaum
M
M
Koslowski
B
B
Quabeck
K
K
Kuse
R
R
Büchner
T
T
Hiddemann
W
W
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D015479:Leukemia, Myelomonocytic, Acute / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013866:Thioguanine / Q000008:administration & dosage; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use*
D003561:Cytarabine; D008942:Mitoxantrone; D014700:Verapamil; D013866:Thioguanine; D003630:Daunorubicin